Pharmafile Logo
Pharmafocus logo
Advanced Search

heart failure

Showing 15 posts of 29 posts found.

FDA approves Eko Health’s AI for heart failure detection

April 3, 2024
Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction

Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …

News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …

News

AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death

May 9, 2023
Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …

News
dw-anzcxqaqavhl

FDA panel backs Novartis’ Entresto for different form of heart disease

December 16, 2020
Research and Development FDA, Novartis, heart failure

Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …

News
shutterstock

Amgen and Cytokinetics’ drug falls short in heart failure despite hitting primary goal

October 9, 2020
Medical Communications Amgen, cytokines, heart failure, pharma

New Phase 3 data has come to light on Amgen and Cytokinetics’ cardiac myosin activator therapy omecamtiv mecarbil fell short …

News
fda2outsideweb

AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction

May 6, 2020
Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …

News
mjg5mzc4oa

Type 2 diabetes drug Rosiglitazone increases risk of heart problems

February 12, 2020
Research and Development British Medical Journal, diabetes, heart failure, insulin, type 2, type 2 diabetes

A new study has given further evidence that rosiglitazone can contribute to risk of heart problems and heart failure. The …

News
novartis_outside_1

Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients

September 2, 2019
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …

News
novartis_side_building

Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction

July 29, 2019
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …

News
novartis_window

Novartis’ Entresto tops enalapril in stabilised heart failure patients

November 13, 2018
Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …

News
astrazeneca_plaque

AstraZeneca jettisons European heart drug rights for $210m

July 24, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …

News
Bayer

Bayer expands Broad Institute partnership to focus on heart failure

July 3, 2018
Manufacturing and Production, Research and Development Bayer, broad institute, collaboration, heart failure, pharma

The Broad Institute of MIT and Harvard has expanded its partnership with Bayer through the launch of the Precision Cardiology …

News
novartis_outside_1

Novartis’ Entresto helps preserve kidney function in chronic heart failure patients

April 16, 2018
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …

News
shutterstock_92671375

Teva spared payout to GSK over patent infringement dispute

March 29, 2018
Sales and Marketing Coreg, GSK, GlaxoSmithKline, Teva, carvedilol, heart failure, pharma

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that …

News
choles

Battling misinformation on the world’s biggest killer

August 14, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cardiovascular disease, cholesterol, healthcare, heart disease, heart failure, medicine, pharma, pharmaceutical

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …

Feature

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024